These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10752591)

  • 21. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).
    Olanow CW; Damier P; Goetz CG; Mueller T; Nutt J; Rascol O; Serbanescu A; Deckers F; Russ H
    Clin Neuropharmacol; 2004; 27(2):58-62. PubMed ID: 15252265
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanisms underlying cortical resonant states: implications for levodopa-induced dyskinesia.
    Richter U; Halje P; Petersson P
    Rev Neurosci; 2013; 24(4):415-29. PubMed ID: 23907419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.
    Pahwa R; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S35-52. PubMed ID: 15501365
    [No Abstract]   [Full Text] [Related]  

  • 25. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 26. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 27. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Atypical corticobasal degeneration with clinical pictures of Parkinson's disease--an L-dopa-effective case].
    Kagamihara Y
    Brain Nerve; 2007 Jun; 59(6):637-45. PubMed ID: 17585597
    [No Abstract]   [Full Text] [Related]  

  • 29. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
    Ghiglieri V; Picconi B; Calabresi P
    Mov Disord; 2010 Aug; 25(11):1527-9. PubMed ID: 20623774
    [No Abstract]   [Full Text] [Related]  

  • 30. Glutamate release inhibition ineffective in levodopa-induced motor complications.
    Bara-Jimenez W; Dimitrova TD; Sherzai A; Aksu M; Chase TN
    Mov Disord; 2006 Sep; 21(9):1380-3. PubMed ID: 16758479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular imaging of levodopa-induced dyskinesias.
    Niccolini F; Rocchi L; Politis M
    Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agonists versus levodopa in PD: the thrilla of whitha.
    Montgomery EB
    Neurology; 2003 Nov; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
    [No Abstract]   [Full Text] [Related]  

  • 33. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Kordower JH
    Mov Disord; 2017 Apr; 32(4):483-484. PubMed ID: 28425143
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis.
    Graybiel AM; Canales JJ; Capper-Loup C
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S71-7. PubMed ID: 11052223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Management of levodopa-induced dyskinesia].
    Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism.
    Dethy S; Van Blercom N; Damhaut P; Wikler D; Hildebrand J; Goldman S
    Mov Disord; 1998 Mar; 13(2):275-80. PubMed ID: 9539341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical-pathological study of levodopa complications.
    Rajput AH; Fenton ME; Birdi S; Macaulay R; George D; Rozdilsky B; Ang LC; Senthilselvan A; Hornykiewicz O
    Mov Disord; 2002 Mar; 17(2):289-96. PubMed ID: 11921114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bipolar affective disorder and unilateral parkinsonism after a brainstem infarction.
    Kulisevsky J; Avila A; Berthier ML
    Mov Disord; 1995 Nov; 10(6):799-802. PubMed ID: 8750004
    [No Abstract]   [Full Text] [Related]  

  • 40. Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
    Wang L; Wang M; Si Q; Yuan Y; Ma K; Gan C; Zhang K
    Parkinsonism Relat Disord; 2019 Oct; 67():36-41. PubMed ID: 31621605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.